You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLopinavir
Accession NumberDB01601  (EXPT00388)
TypeSmall Molecule
GroupsApproved
DescriptionLopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.
Structure
Thumb
Synonyms
LPV
External Identifiers
  • A-157378-0
  • A-157378.0
  • ABT-378
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AluviranNot Available
KoletraNot Available
Brand mixtures
NameLabellerIngredients
KaletraAbb Vie Inc.
SaltsNot Available
Categories
UNII2494G1JF75
CAS number192725-17-0
WeightAverage: 628.8008
Monoisotopic: 628.362470666
Chemical FormulaC37H48N4O5
InChI KeyInChIKey=KJHKTHWMRKYKJE-SUGCFTRWSA-N
InChI
InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
IUPAC Name
(2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
SMILES
CC(C)[[email protected]](N1CCCNC1=O)C(=O)N[[email protected]](C[[email protected]](O)[[email protected]](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenol ether
  • Pyrimidone
  • Alkyl aryl ether
  • Fatty acyl
  • Pyrimidine
  • N-acyl-amine
  • Fatty amide
  • 1,3-diazinane
  • Urea
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIndicated in combination with other antiretroviral agents for the treatment of HIV-infection.
PharmacodynamicsLopinavir is an antiretroviral of the protease inhibitor class. Inhibiting HIV-1 protease (responsible for protein cleavage), results in selectively inhibiting the cleavage of HIV gag and gag-pol polyproteins, thereby preventing viral maturation.
Mechanism of actionLopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles.
Related Articles
AbsorptionAdministered alone, lopinavir has insufficient bioavailability; however, like several HIV protease inhibitors, its blood levels are greatly increased by low doses of ritonavir, a potent inhibitor of cytochrome P450 3A4.
Volume of distributionNot Available
Protein bindingLopinavir is highly bound to plasma proteins (98-99%).
Metabolism

Hepatic. Lopinavir is extensively metabolized by the hepatic cytochrome P450 system, almost exclusively by the CYP3A isozyme.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityAlthough human experience of acute overdosage with lopinavir is limited, accidental ingestion of the product by a young child could result in significant alcohol-related toxicity and could approach the potential lethal dose of alcohol.
Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.6593
Blood Brain Barrier-0.9916
Caco-2 permeable+0.8856
P-glycoprotein substrateSubstrate0.8755
P-glycoprotein inhibitor IInhibitor0.7355
P-glycoprotein inhibitor IIInhibitor0.5277
Renal organic cation transporterNon-inhibitor0.8578
CYP450 2C9 substrateNon-substrate0.7508
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6732
CYP450 1A2 substrateNon-inhibitor0.8935
CYP450 2C9 inhibitorNon-inhibitor0.7326
CYP450 2D6 inhibitorNon-inhibitor0.9438
CYP450 2C19 inhibitorNon-inhibitor0.7983
CYP450 3A4 inhibitorNon-inhibitor0.6469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9054
Ames testNon AMES toxic0.8049
CarcinogenicityNon-carcinogens0.7865
BiodegradationNot ready biodegradable0.9182
Rat acute toxicity2.2503 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8605
hERG inhibition (predictor II)Inhibitor0.8475
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral
Solutionoral
Tabletoral
Tablet, film coatedoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5914332 Yes1996-06-132016-06-13Us
US6037157 Yes1996-12-262016-12-26Us
US6232333 Yes1998-05-072018-05-07Us
US6284767 Yes1996-08-152016-08-15Us
US6458818 Yes1998-05-072018-05-07Us
US6521651 Yes1998-05-072018-05-07Us
US6703403 Yes1996-12-262016-12-26Us
US6911214 Yes2002-05-282022-05-28Us
US7141593 Yes2000-11-222020-11-22Us
US7148359 Yes2000-01-192020-01-19Us
US7364752 Yes2001-05-102021-05-10Us
US7432294 Yes2000-11-222020-11-22Us
US8025899 Yes2008-06-142028-06-14Us
US8268349 Yes2005-02-252025-02-25Us
US8309613 Yes2005-06-242025-06-24Us
US8377952 Yes2008-04-222028-04-22Us
US8399015 Yes2005-02-252025-02-25Us
US8470347 Yes2007-03-172027-03-17Us
US8501219 No2001-11-282021-11-28Us
US8691878 Yes2005-02-252025-02-25Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00192 mg/mLALOGPS
logP3.91ALOGPS
logP4.69ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)13.39ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area120 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity179.36 m3·mol-1ChemAxon
Polarizability69.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US5914332
General ReferencesNot Available
External Links
ATC CodesJ05AR10
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Lopinavir.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lopinavir.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Lopinavir.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Lopinavir.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Lopinavir.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Lopinavir.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Lopinavir.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Lopinavir.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lopinavir.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Lopinavir.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Lopinavir.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Lopinavir.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Lopinavir.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Lopinavir.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Lopinavir.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Lopinavir.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Lopinavir.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Lopinavir.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Lopinavir.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Lopinavir.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Lopinavir.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Lopinavir.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Lopinavir.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Lopinavir.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Lopinavir.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lopinavir.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Lopinavir.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Lopinavir.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Lopinavir.
AmantadineAmantadine may increase the QTc-prolonging activities of Lopinavir.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Lopinavir.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Lopinavir.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Lopinavir.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Lopinavir.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Lopinavir.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Lopinavir.
AmiodaroneLopinavir may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Lopinavir.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Lopinavir.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Lopinavir.
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Lopinavir.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Lopinavir.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Lopinavir.
AmoxicillinThe metabolism of Amoxicillin can be increased when combined with Lopinavir.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Lopinavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Lopinavir.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Lopinavir.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Lopinavir.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Lopinavir.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Lopinavir.
ApomorphineApomorphine may increase the QTc-prolonging activities of Lopinavir.
ApremilastThe metabolism of Apremilast can be decreased when combined with Lopinavir.
AprepitantThe serum concentration of Lopinavir can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Lopinavir.
AprindineThe metabolism of Aprindine can be decreased when combined with Lopinavir.
ArformoterolArformoterol may increase the QTc-prolonging activities of Lopinavir.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Lopinavir.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Lopinavir.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lopinavir.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Lopinavir.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Lopinavir.
ArtemetherLopinavir may increase the QTc-prolonging activities of Artemether.
AsenapineLopinavir may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Lopinavir.
AtazanavirThe metabolism of Lopinavir can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Lopinavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Lopinavir.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Lopinavir.
AtomoxetineThe metabolism of Lopinavir can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Lopinavir.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Lopinavir.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Lopinavir.
AzelastineThe metabolism of Azelastine can be decreased when combined with Lopinavir.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Lopinavir.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Lopinavir.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Lopinavir.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Lopinavir.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Lopinavir.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Lopinavir.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Lopinavir.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Lopinavir.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Lopinavir.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Lopinavir.
BepridilThe metabolism of Bepridil can be decreased when combined with Lopinavir.
BeraprostThe metabolism of Beraprost can be decreased when combined with Lopinavir.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Lopinavir.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Lopinavir.
BexaroteneThe serum concentration of Lopinavir can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Lopinavir.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Lopinavir.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Lopinavir.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Lopinavir.
BoceprevirThe serum concentration of Lopinavir can be decreased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Lopinavir.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Lopinavir.
BortezomibThe metabolism of Lopinavir can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Lopinavir can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Lopinavir.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Lopinavir.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Lopinavir.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Lopinavir.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Lopinavir.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Lopinavir.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Lopinavir.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Lopinavir.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Lopinavir.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Lopinavir.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Lopinavir.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Lopinavir.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Lopinavir.
BuserelinBuserelin may increase the QTc-prolonging activities of Lopinavir.
BuspironeThe metabolism of Buspirone can be decreased when combined with Lopinavir.
BusulfanThe metabolism of Busulfan can be decreased when combined with Lopinavir.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Lopinavir.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Lopinavir.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Lopinavir.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Lopinavir.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Lopinavir.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Lopinavir.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lopinavir.
CaptoprilThe metabolism of Captopril can be decreased when combined with Lopinavir.
CarbamazepineThe metabolism of Lopinavir can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Lopinavir.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Lopinavir.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Lopinavir.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Lopinavir.
CarisoprodolThe metabolism of Carisoprodol can be increased when combined with Lopinavir.
CarteololThe metabolism of Carteolol can be decreased when combined with Lopinavir.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Lopinavir.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lopinavir.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Lopinavir.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Lopinavir.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Lopinavir.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Lopinavir.
CeritinibCeritinib may increase the QTc-prolonging activities of Lopinavir.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Lopinavir.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Lopinavir.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Lopinavir.
ChloramphenicolThe metabolism of Chloramphenicol can be increased when combined with Lopinavir.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Lopinavir.
ChloroquineChloroquine may increase the QTc-prolonging activities of Lopinavir.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Lopinavir.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Lopinavir.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Lopinavir.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Lopinavir.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lopinavir.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Lopinavir.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Lopinavir.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Lopinavir.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lopinavir.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Lopinavir.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Lopinavir.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Lopinavir.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Lopinavir.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Lopinavir.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Lopinavir.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Lopinavir.
CisaprideCisapride may increase the QTc-prolonging activities of Lopinavir.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Lopinavir.
CitalopramCitalopram may increase the QTc-prolonging activities of Lopinavir.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Lopinavir.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Lopinavir.
ClemastineThe metabolism of Lopinavir can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Lopinavir.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Lopinavir.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Lopinavir.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Lopinavir.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Lopinavir.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Lopinavir.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Lopinavir.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Lopinavir.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Lopinavir.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Lopinavir.
ClomipramineClomipramine may increase the QTc-prolonging activities of Lopinavir.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Lopinavir.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Lopinavir.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Lopinavir.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Lopinavir.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Lopinavir.
ClotrimazoleThe metabolism of Lopinavir can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Lopinavir.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Lopinavir.
CobicistatThe metabolism of Lopinavir can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Lopinavir.
CocaineThe metabolism of Cocaine can be decreased when combined with Lopinavir.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Lopinavir.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Lopinavir.
ConivaptanThe serum concentration of Lopinavir can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Lopinavir.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Lopinavir.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Lopinavir.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Lopinavir.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lopinavir.
CyclophosphamideThe risk or severity of adverse effects can be increased when Lopinavir is combined with Cyclophosphamide.
CyclosporineThe metabolism of Lopinavir can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Lopinavir.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Lopinavir.
DabrafenibThe serum concentration of Lopinavir can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Lopinavir.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Lopinavir.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Lopinavir.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Lopinavir.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Lopinavir.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Lopinavir.
DapsoneThe metabolism of Dapsone can be decreased when combined with Lopinavir.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Lopinavir.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Lopinavir.
DarunavirThe metabolism of Lopinavir can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Lopinavir.
DasatinibThe serum concentration of Lopinavir can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Lopinavir.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Lopinavir.
DeferasiroxThe serum concentration of Lopinavir can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Lopinavir.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Lopinavir.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Lopinavir.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Lopinavir.
DelavirdineThe metabolism of Lopinavir can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Lopinavir.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Lopinavir.
DesipramineDesipramine may increase the QTc-prolonging activities of Lopinavir.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Lopinavir.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Lopinavir.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Lopinavir.
DexamethasoneThe serum concentration of Lopinavir can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Lopinavir.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Lopinavir.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Lopinavir.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Lopinavir.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Lopinavir.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Lopinavir.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Lopinavir.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Lopinavir.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Lopinavir.
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Lopinavir.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Lopinavir.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Lopinavir.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Lopinavir.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Lopinavir.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Lopinavir.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Lopinavir.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lopinavir.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Lopinavir.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Lopinavir.
DihydroergotamineThe metabolism of Lopinavir can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Lopinavir.
DiltiazemThe metabolism of Lopinavir can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Lopinavir.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Lopinavir.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Lopinavir.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Lopinavir.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Lopinavir.
DisulfiramThe risk or severity of adverse effects can be increased when Lopinavir is combined with Disulfiram.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Lopinavir.
DofetilideDofetilide may increase the QTc-prolonging activities of Lopinavir.
DolasetronDolasetron may increase the QTc-prolonging activities of Lopinavir.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Lopinavir.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Lopinavir.
DomperidoneDomperidone may increase the QTc-prolonging activities of Lopinavir.
DonepezilThe metabolism of Donepezil can be decreased when combined with Lopinavir.
DopamineThe metabolism of Dopamine can be decreased when combined with Lopinavir.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Lopinavir.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Lopinavir.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Lopinavir.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Lopinavir.
DoxepinDoxepin may increase the QTc-prolonging activities of Lopinavir.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lopinavir.
DoxycyclineThe metabolism of Lopinavir can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Lopinavir.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Lopinavir.
DronedaroneDronedarone may increase the QTc-prolonging activities of Lopinavir.
DroperidolDroperidol may increase the QTc-prolonging activities of Lopinavir.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Lopinavir.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lopinavir.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Lopinavir.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Lopinavir.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Lopinavir.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Lopinavir.
EfavirenzThe serum concentration of Lopinavir can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Lopinavir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Lopinavir.
EliglustatLopinavir may increase the QTc-prolonging activities of Eliglustat.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Lopinavir.
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Lopinavir.
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Lopinavir.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Lopinavir.
EncainideThe metabolism of Encainide can be decreased when combined with Lopinavir.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Lopinavir.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Lopinavir.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Lopinavir.
EnzalutamideThe serum concentration of Lopinavir can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Lopinavir.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Lopinavir.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Lopinavir.
EquilinThe serum concentration of Equilin can be increased when it is combined with Lopinavir.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Lopinavir.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lopinavir.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Lopinavir.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Lopinavir.
EribulinEribulin may increase the QTc-prolonging activities of Lopinavir.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Lopinavir.
ErythromycinErythromycin may increase the QTc-prolonging activities of Lopinavir.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Lopinavir.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Lopinavir.
Eslicarbazepine acetateThe serum concentration of Lopinavir can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Lopinavir.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Lopinavir.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Lopinavir.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Lopinavir.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Lopinavir.
EstramustineThe metabolism of Estramustine can be decreased when combined with Lopinavir.
EstriolThe serum concentration of Estriol can be increased when it is combined with Lopinavir.
EstroneThe serum concentration of Estrone can be increased when it is combined with Lopinavir.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Lopinavir.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Lopinavir.
EthanolThe metabolism of Ethanol can be decreased when combined with Lopinavir.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lopinavir.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Lopinavir.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Lopinavir.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Lopinavir.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Lopinavir.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Lopinavir.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Lopinavir.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Lopinavir.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Lopinavir.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Lopinavir.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Lopinavir.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Lopinavir.
EzogabineEzogabine may increase the QTc-prolonging activities of Lopinavir.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Lopinavir.
FamotidineFamotidine may increase the QTc-prolonging activities of Lopinavir.
FamotidineThe metabolism of Famotidine can be increased when combined with Lopinavir.
FelbamateThe metabolism of Felbamate can be decreased when combined with Lopinavir.
FelbamateFelbamate may increase the QTc-prolonging activities of Lopinavir.
FelodipineThe metabolism of Felodipine can be decreased when combined with Lopinavir.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Lopinavir.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Lopinavir.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lopinavir.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Lopinavir.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Lopinavir.
FinasterideThe metabolism of Finasteride can be decreased when combined with Lopinavir.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Lopinavir.
FingolimodFingolimod may increase the QTc-prolonging activities of Lopinavir.
FlecainideFlecainide may increase the QTc-prolonging activities of Lopinavir.
FlecainideThe metabolism of Flecainide can be decreased when combined with Lopinavir.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Lopinavir.
FluconazoleThe metabolism of Lopinavir can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Lopinavir.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Lopinavir.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Lopinavir.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Lopinavir.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Lopinavir.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Lopinavir.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Lopinavir.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Lopinavir.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Lopinavir.
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Lopinavir.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Lopinavir.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Lopinavir.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Lopinavir.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Lopinavir.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Lopinavir.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Lopinavir.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Lopinavir.
FlutamideThe metabolism of Flutamide can be decreased when combined with Lopinavir.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Lopinavir.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Lopinavir.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Lopinavir.
FluvoxamineThe metabolism of Lopinavir can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Lopinavir.
FormoterolThe metabolism of Formoterol can be decreased when combined with Lopinavir.
FosamprenavirThe serum concentration of Lopinavir can be decreased when it is combined with Fosamprenavir.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Lopinavir.
FosaprepitantThe serum concentration of Lopinavir can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Lopinavir.
FosphenytoinThe serum concentration of Lopinavir can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe metabolism of Fosphenytoin can be increased when combined with Lopinavir.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Lopinavir.
Fusidic AcidThe serum concentration of Lopinavir can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Lopinavir.
GalantamineThe metabolism of Galantamine can be decreased when combined with Lopinavir.
GalantamineGalantamine may increase the QTc-prolonging activities of Lopinavir.
GarlicThe serum concentration of Lopinavir can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Lopinavir.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Lopinavir.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Lopinavir.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Lopinavir.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lopinavir.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Lopinavir.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Lopinavir.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Lopinavir.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lopinavir.
GlucosamineThe metabolism of Glucosamine can be increased when combined with Lopinavir.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Lopinavir.
GoserelinGoserelin may increase the QTc-prolonging activities of Lopinavir.
GranisetronGranisetron may increase the QTc-prolonging activities of Lopinavir.
GranisetronThe metabolism of Granisetron can be decreased when combined with Lopinavir.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Lopinavir.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Lopinavir.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Lopinavir.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Lopinavir.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Lopinavir.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Lopinavir.
HalothaneThe metabolism of Halothane can be decreased when combined with Lopinavir.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Lopinavir.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Lopinavir.
HistrelinHistrelin may increase the QTc-prolonging activities of Lopinavir.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Lopinavir.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Lopinavir.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Lopinavir.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Lopinavir.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Lopinavir.
IbandronateIbandronate may increase the QTc-prolonging activities of Lopinavir.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Lopinavir.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Lopinavir.
IbutilideIbutilide may increase the QTc-prolonging activities of Lopinavir.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Lopinavir.
IdelalisibThe serum concentration of Lopinavir can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Lopinavir resulting in a loss in efficacy.
IloperidoneLopinavir may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Lopinavir.
ImatinibThe metabolism of Lopinavir can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Lopinavir.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Lopinavir.
ImipramineImipramine may increase the QTc-prolonging activities of Lopinavir.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Lopinavir.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Lopinavir.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Lopinavir.
IndapamideThe metabolism of Indapamide can be decreased when combined with Lopinavir.
IndapamideIndapamide may increase the QTc-prolonging activities of Lopinavir.
IndinavirThe metabolism of Lopinavir can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Lopinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Lopinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lopinavir.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lopinavir.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lopinavir.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lopinavir.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lopinavir.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lopinavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Lopinavir.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Lopinavir.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Lopinavir.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Lopinavir.
IsavuconazoniumThe metabolism of Lopinavir can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Lopinavir.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lopinavir.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Lopinavir.
IsradipineThe metabolism of Lopinavir can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Lopinavir.
ItraconazoleThe metabolism of Lopinavir can be decreased when combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Lopinavir.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Lopinavir.
IvacaftorThe serum concentration of Lopinavir can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Lopinavir.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Lopinavir.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Lopinavir.
KetamineThe metabolism of Ketamine can be decreased when combined with Lopinavir.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Lopinavir.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Lopinavir.
KetoconazoleThe serum concentration of Lopinavir can be increased when it is combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Lopinavir.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Lopinavir.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Lopinavir.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Lopinavir.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Lopinavir.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Lopinavir.
LapatinibLapatinib may increase the QTc-prolonging activities of Lopinavir.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Lopinavir.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Lopinavir.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Lopinavir.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Lopinavir.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Lopinavir.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Lopinavir.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Lopinavir.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Lopinavir.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Lopinavir.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Lopinavir.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Lopinavir.
LevodopaThe metabolism of Levodopa can be decreased when combined with Lopinavir.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Lopinavir.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Lopinavir.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Lopinavir.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Lopinavir.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Lopinavir.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Lopinavir.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Lopinavir.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Lopinavir.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Lopinavir.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Lopinavir.
LisurideThe metabolism of Lisuride can be decreased when combined with Lopinavir.
LithiumLithium may increase the QTc-prolonging activities of Lopinavir.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Lopinavir.
LomustineThe metabolism of Lomustine can be decreased when combined with Lopinavir.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Lopinavir.
LosartanThe serum concentration of Losartan can be increased when it is combined with Lopinavir.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Lopinavir.
LovastatinThe metabolism of Lopinavir can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Lopinavir can be increased when it is combined with Luliconazole.
LumefantrineLopinavir may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Lopinavir.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Lopinavir.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Lopinavir.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Lopinavir.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Lopinavir.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Lopinavir.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Lopinavir.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Lopinavir.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Lopinavir.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Lopinavir.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Lopinavir.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Lopinavir.
MefloquineMefloquine may increase the QTc-prolonging activities of Lopinavir.
MelatoninThe metabolism of Melatonin can be increased when combined with Lopinavir.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Lopinavir.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Lopinavir.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Lopinavir.
MeprobamateThe metabolism of Meprobamate can be increased when combined with Lopinavir.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Lopinavir.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Lopinavir.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.
MethadoneMethadone may increase the QTc-prolonging activities of Lopinavir.
MethadoneThe metabolism of Methadone can be decreased when combined with Lopinavir.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Lopinavir.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Lopinavir.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lopinavir.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Lopinavir.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Lopinavir.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Lopinavir.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Lopinavir.
MethsuximideThe metabolism of Methsuximide can be increased when combined with Lopinavir.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Lopinavir.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be increased when combined with Lopinavir.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Lopinavir.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Lopinavir.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Lopinavir.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Lopinavir.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Lopinavir.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Lopinavir.
MetronidazoleThe risk or severity of adverse effects can be increased when Metronidazole is combined with Lopinavir.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Lopinavir.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Lopinavir.
MianserinThe metabolism of Mianserin can be decreased when combined with Lopinavir.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Lopinavir.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Lopinavir.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Lopinavir.
MifepristoneMifepristone may increase the QTc-prolonging activities of Lopinavir.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lopinavir.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Lopinavir.
MinaprineThe metabolism of Minaprine can be decreased when combined with Lopinavir.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Lopinavir.
MirabegronMirabegron may increase the QTc-prolonging activities of Lopinavir.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Lopinavir.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Lopinavir.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lopinavir.
MitotaneThe serum concentration of Lopinavir can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Lopinavir.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Lopinavir.
ModafinilThe serum concentration of Lopinavir can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Lopinavir.
MoexiprilMoexipril may increase the QTc-prolonging activities of Lopinavir.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Lopinavir.
MontelukastThe metabolism of Montelukast can be decreased when combined with Lopinavir.
MorphineThe serum concentration of Morphine can be increased when it is combined with Lopinavir.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Lopinavir.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Lopinavir.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lopinavir.
NadololThe serum concentration of Nadolol can be increased when it is combined with Lopinavir.
NafcillinThe serum concentration of Lopinavir can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Lopinavir.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Lopinavir.
NaproxenThe metabolism of Naproxen can be decreased when combined with Lopinavir.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Lopinavir.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Lopinavir.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Lopinavir.
NefazodoneThe metabolism of Lopinavir can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Lopinavir.
NetupitantThe serum concentration of Lopinavir can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Lopinavir.
NevirapineThe metabolism of Lopinavir can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Lopinavir.
NicardipineNicardipine may increase the QTc-prolonging activities of Lopinavir.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Lopinavir.
NicotineThe metabolism of Nicotine can be decreased when combined with Lopinavir.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Lopinavir.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Lopinavir.
NilotinibNilotinib may increase the QTc-prolonging activities of Lopinavir.
NilutamideThe metabolism of Nilutamide can be increased when combined with Lopinavir.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Lopinavir.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Lopinavir.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Lopinavir.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Lopinavir.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Lopinavir.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Lopinavir.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Lopinavir.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Lopinavir.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Lopinavir.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Lopinavir.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Lopinavir.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Lopinavir.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Lopinavir.
OctreotideOctreotide may increase the QTc-prolonging activities of Lopinavir.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Lopinavir.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Lopinavir.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Lopinavir.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Lopinavir.
OlaparibThe metabolism of Lopinavir can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Lopinavir.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Lopinavir.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Lopinavir.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Lopinavir.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Lopinavir.
OndansetronOndansetron may increase the QTc-prolonging activities of Lopinavir.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Lopinavir.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Lopinavir.
OsimertinibThe serum concentration of Lopinavir can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Lopinavir.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Lopinavir.
OxiconazoleThe metabolism of Oxiconazole can be increased when combined with Lopinavir.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Lopinavir.
OxycodoneThe risk or severity of adverse effects can be increased when Lopinavir is combined with Oxycodone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Lopinavir.
OxytocinOxytocin may increase the QTc-prolonging activities of Lopinavir.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Lopinavir.
PalbociclibThe serum concentration of Lopinavir can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the QTc-prolonging activities of Lopinavir.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Lopinavir.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Lopinavir.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Lopinavir.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Lopinavir.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Lopinavir.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Lopinavir.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Lopinavir.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Lopinavir.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Lopinavir.
ParoxetineParoxetine may increase the QTc-prolonging activities of Lopinavir.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Lopinavir.
PasireotidePasireotide may increase the QTc-prolonging activities of Lopinavir.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Lopinavir.
PazopanibPazopanib may increase the QTc-prolonging activities of Lopinavir.
PentamidinePentamidine may increase the QTc-prolonging activities of Lopinavir.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Lopinavir.
PentobarbitalThe metabolism of Lopinavir can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Lopinavir.
PerflutrenPerflutren may increase the QTc-prolonging activities of Lopinavir.
PergolideThe metabolism of Pergolide can be decreased when combined with Lopinavir.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Lopinavir.
PermethrinThe metabolism of Permethrin can be decreased when combined with Lopinavir.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Lopinavir.
PethidineThe risk or severity of adverse effects can be increased when Lopinavir is combined with Pethidine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Lopinavir.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Lopinavir.
PhenobarbitalThe serum concentration of Lopinavir can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Lopinavir.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Lopinavir.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Lopinavir.
PhenytoinThe serum concentration of Lopinavir can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Lopinavir.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Lopinavir.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Lopinavir.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Lopinavir.
PimozidePimozide may increase the QTc-prolonging activities of Lopinavir.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Lopinavir.
PindololThe metabolism of Pindolol can be decreased when combined with Lopinavir.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lopinavir.
PiperazineThe metabolism of Piperazine can be decreased when combined with Lopinavir.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Lopinavir.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Lopinavir.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Lopinavir.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Lopinavir.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Lopinavir.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Lopinavir.
PosaconazoleThe metabolism of Lopinavir can be decreased when combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Lopinavir.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Lopinavir.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Lopinavir resulting in a loss in efficacy.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Lopinavir.
PrazepamThe metabolism of Prazepam can be decreased when combined with Lopinavir.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Lopinavir.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Lopinavir.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Lopinavir.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Lopinavir.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Lopinavir.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Lopinavir.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Lopinavir.
PrimidoneThe metabolism of Lopinavir can be increased when combined with Primidone.
ProcainamideProcainamide may increase the QTc-prolonging activities of Lopinavir.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Lopinavir.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Lopinavir.
ProguanilThe metabolism of Proguanil can be decreased when combined with Lopinavir.
PromazinePromazine may increase the QTc-prolonging activities of Lopinavir.
PromazineThe metabolism of Promazine can be decreased when combined with Lopinavir.
PromethazinePromethazine may increase the QTc-prolonging activities of Lopinavir.
PromethazineThe metabolism of Promethazine can be decreased when combined with Lopinavir.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Lopinavir.
PropafenonePropafenone may increase the QTc-prolonging activities of Lopinavir.
PropofolThe metabolism of Propofol can be decreased when combined with Lopinavir.
PropofolPropofol may increase the QTc-prolonging activities of Lopinavir.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Lopinavir.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Lopinavir.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Lopinavir.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Lopinavir.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Lopinavir.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Lopinavir.
QuazepamThe metabolism of Quazepam can be decreased when combined with Lopinavir.
QuetiapineQuetiapine may increase the QTc-prolonging activities of Lopinavir.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Lopinavir.
QuinidineLopinavir may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Lopinavir.
QuinineQuinine may increase the QTc-prolonging activities of Lopinavir.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Lopinavir.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Lopinavir.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Lopinavir.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Lopinavir.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Lopinavir.
RanolazineThe metabolism of Lopinavir can be decreased when combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Lopinavir.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Lopinavir.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Lopinavir.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Lopinavir.
repinotanThe metabolism of repinotan can be decreased when combined with Lopinavir.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Lopinavir.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Lopinavir.
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Lopinavir.
RifabutinThe metabolism of Lopinavir can be increased when combined with Rifabutin.
RifampicinThe risk or severity of adverse effects can be increased when Rifampicin is combined with Lopinavir.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Lopinavir.
RifapentineThe metabolism of Lopinavir can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Lopinavir.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Lopinavir.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Lopinavir.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Lopinavir.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Lopinavir.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Lopinavir.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Lopinavir.
RisperidoneRisperidone may increase the QTc-prolonging activities of Lopinavir.
RitonavirThe metabolism of Lopinavir can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Lopinavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Lopinavir.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Lopinavir.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Lopinavir.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Lopinavir.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Lopinavir.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Lopinavir.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lopinavir.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Lopinavir.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Lopinavir.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Lopinavir.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Lopinavir.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Lopinavir.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Lopinavir.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Lopinavir.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Lopinavir.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Lopinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Lopinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lopinavir.
SelegilineThe metabolism of Selegiline can be decreased when combined with Lopinavir.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Lopinavir.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Lopinavir.
SertindoleThe metabolism of Sertindole can be decreased when combined with Lopinavir.
SertralineThe metabolism of Sertraline can be decreased when combined with Lopinavir.
SertralineSertraline may increase the QTc-prolonging activities of Lopinavir.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Lopinavir.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Lopinavir.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Lopinavir.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Lopinavir.
SildenafilThe metabolism of Lopinavir can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Lopinavir.
SiltuximabThe serum concentration of Lopinavir can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Lopinavir can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lopinavir.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Lopinavir.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lopinavir.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Lopinavir.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Lopinavir.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Lopinavir.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Lopinavir.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Lopinavir.
SorafenibSorafenib may increase the QTc-prolonging activities of Lopinavir.
SotalolSotalol may increase the QTc-prolonging activities of Lopinavir.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Lopinavir.
SparteineThe metabolism of Sparteine can be decreased when combined with Lopinavir.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Lopinavir.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Lopinavir.
St. John's WortThe metabolism of Lopinavir can be increased when combined with St. John's Wort.
StiripentolThe serum concentration of Lopinavir can be increased when it is combined with Stiripentol.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Lopinavir.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Lopinavir.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Lopinavir.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Lopinavir.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Lopinavir.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Lopinavir.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lopinavir.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Lopinavir.
SunitinibSunitinib may increase the QTc-prolonging activities of Lopinavir.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Lopinavir.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Lopinavir.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Lopinavir.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Lopinavir.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Lopinavir.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Lopinavir resulting in a loss in efficacy.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Lopinavir.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Lopinavir.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Lopinavir.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Lopinavir.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Lopinavir.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Lopinavir.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Lopinavir.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Lopinavir.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Lopinavir.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Lopinavir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Lopinavir.
TelaprevirThe metabolism of Lopinavir can be decreased when combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Lopinavir.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Lopinavir.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Lopinavir.
TemazepamThe metabolism of Temazepam can be decreased when combined with Lopinavir.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Lopinavir.
TeniposideThe metabolism of Teniposide can be decreased when combined with Lopinavir.
TenofovirLopinavir may increase the nephrotoxic activities of Tenofovir.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Lopinavir.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Lopinavir.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Lopinavir.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Lopinavir.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Lopinavir.
TetrabenazineLopinavir may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Lopinavir.
ThalidomideThe metabolism of Thalidomide can be increased when combined with Lopinavir.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Lopinavir.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lopinavir.
ThioridazineThioridazine may increase the QTc-prolonging activities of Lopinavir.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Lopinavir.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Lopinavir.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Lopinavir.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Lopinavir.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Lopinavir resulting in a loss in efficacy.
TiclopidineThe metabolism of Lopinavir can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Lopinavir.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Lopinavir.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Lopinavir.
TipranavirThe serum concentration of Lopinavir can be decreased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Lopinavir.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Lopinavir.
TizanidineTizanidine may increase the QTc-prolonging activities of Lopinavir.
TocilizumabThe serum concentration of Lopinavir can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Lopinavir.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lopinavir.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lopinavir.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Lopinavir.
TolterodineTolterodine may increase the QTc-prolonging activities of Lopinavir.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Lopinavir.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Lopinavir.
TorasemideThe metabolism of Torasemide can be decreased when combined with Lopinavir.
ToremifeneThe risk or severity of adverse effects can be increased when Lopinavir is combined with Toremifene.
ToremifeneToremifene may increase the QTc-prolonging activities of Lopinavir.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Lopinavir.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Lopinavir.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Lopinavir.
TrazodoneLopinavir may increase the QTc-prolonging activities of Trazodone.
TreprostinilThe serum concentration of Treprostinil can be increased when it is combined with Lopinavir.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Lopinavir.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Lopinavir.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Lopinavir.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Lopinavir.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Lopinavir.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Lopinavir.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Lopinavir.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Lopinavir.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Lopinavir.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Lopinavir.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Lopinavir.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Lopinavir.
UdenafilThe metabolism of Udenafil can be decreased when combined with Lopinavir.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Lopinavir.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Lopinavir.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Lopinavir.
Valproic AcidThe metabolism of Valproic Acid can be increased when combined with Lopinavir.
VandetanibLopinavir may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Lopinavir.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Lopinavir.
VardenafilVardenafil may increase the QTc-prolonging activities of Lopinavir.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Lopinavir.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Lopinavir.
VemurafenibVemurafenib may increase the QTc-prolonging activities of Lopinavir.
VenlafaxineThe metabolism of Lopinavir can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Lopinavir.
VerapamilThe metabolism of Lopinavir can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Lopinavir.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Lopinavir.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Lopinavir.
VilanterolVilanterol may increase the QTc-prolonging activities of Lopinavir.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Lopinavir.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lopinavir.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Lopinavir.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Lopinavir.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Lopinavir.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Lopinavir.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Lopinavir.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Lopinavir.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Lopinavir.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Lopinavir.
VoriconazoleThe metabolism of Lopinavir can be decreased when combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Lopinavir.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Lopinavir.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Lopinavir.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Lopinavir.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Lopinavir.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Lopinavir.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Lopinavir.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Lopinavir.
ZileutonThe metabolism of Zileuton can be decreased when combined with Lopinavir.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Lopinavir.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Lopinavir.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Lopinavir.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Lopinavir.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Lopinavir.
ZuclopenthixolLopinavir may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid St.John's Wort.
  • Take with food.

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Aspartic-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72874
Molecular Weight:
10778.7 Da
References
  1. Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28. [PubMed:17854027 ]
  2. Reddy GS, Ali A, Nalam MN, Anjum SG, Cao H, Nathans RS, Schiffer CA, Rana TM: Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem. 2007 Sep 6;50(18):4316-28. Epub 2007 Aug 16. [PubMed:17696512 ]
  3. Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Authors unspecified: Lopinavir/ritonavir: a protease inhibitor combination. Med Lett Drugs Ther. 2001 Jan 8;43(1095):1-2. [PubMed:11151088 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ: Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2003 May 2;17(7):1092-4. [PubMed:12700464 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 12:45 / Updated on September 29, 2016 03:39